Modality
Radioligand
MOA
IL-13i
Target
KRASG12C
Pathway
STING
MCCSCDPsoriasis
Development Pipeline
Preclinical
Jun 2019
→ Jan 2030
PreclinicalCurrent
NCT08559633
1,947 pts·SCD
2019-06→2030-01·Not yet recruiting
NCT03244024
1,520 pts·SCD
2019-09→2029-06·Active
3,467 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-06-213.2y awayInterim· SCD
2030-01-063.8y awayInterim· SCD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2029-06-21 · 3.2y away
SCD
Interim
2030-01-06 · 3.8y away
SCD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08559633 | Preclinical | SCD | Not yet recr... | 1947 | UPDRS |
| NCT03244024 | Preclinical | SCD | Active | 1520 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |